Navigation Links
Accera, Inc. Completes $35 Million Series C Financing
Date:11/11/2008

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. Proceeds of this financing will be used to begin sales and marketing of the company's lead product, Axona(TM) (previously known as Ketasyn), which is scheduled to launch in the United States in the first quarter of 2009.

Inventages was joined in this round by San Diego-based POSCO BioVentures and other previous private investors. Inventages and POSCO participated in the Company's Series A and B rounds.

Steve Orndorff, Ph.D., Accera's founder and CEO, said, "Closing this transaction in the current difficult financial environment is a testament to the confidence of our investors in the Accera organization and the potential of Axona".

Wolfgang Reichenberger, Ph.D., general partner, Inventages WHealth Management Inc. and IVC Americas SA and a member of Accera's Board of Directors, expressed enthusiasm about the commercial direction of the company and the upcoming launch of Axona. "Metabolic intervention is a new approach to neurodegenerative diseases, and Accera is a clear leader. We are pleased to support the commercialization of Axona as the lead product from this novel technology platform," Reichenberger said.

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies by providing an alternative energy source for the brain. For more information, visit http://www.accerapharma.com.

Contacts

Media: Investors:

Kelly McKenna Greg Kading

MS&L Worldwide Vice President, Finance

(415) 293-2808 Accera, Inc.

Kelly.mckenna@mslworldwide.com (303) 999-3704

gkading@accerapharma.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
2. Accera, Inc. to Present at the 4th Annual BIO Investor Forum
3. OncoMed Pharmaceuticals Completes Series B Financing
4. Avantium Completes EUR 18 Million Financing Round
5. Advanced Life Sciences Completes Debt Transaction
6. American Oriental Bioengineering Completes Two Acquisitions
7. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
8. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
9. S*BIO Completes US$26 Million Equity Financing
10. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
11. CeNeRx BioPharma Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):